Imbria Pharmaceuticals Completes Enrollment in Phase II IMPROVE-HCM Trial of Ninerafaxstat in Patients With Non-Obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals, Inc. announced that it has completed enrollment in the IMPROVE-HCM Phase II placebo-controlled clinical trial of ninerafaxstat with 67 patients with non-obstructive hypertrophic cardiomyopathy randomized.